CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland

  • ID: 4586861
  • Report
  • Region: Switzerland
  • 124 pages
  • GlobalData
1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland

Summary

High expenditure on pharmaceutical R&D and the presence of major pharmaceutical companies has propelled the growth of the Swiss healthcare industry. The increasing elderly population and associated disease burden are expected to drive the growth of the pharmaceutical market. Switzerland holds second place following the US in terms of healthcare spending, when compared with healthcare costs.It spends approximately 11.65% of its GDP on healthcare.In 2015 pharmaceutical sales increased to $6.4 billion from $5.5 billion in 2010. The market is forecast to grow to $8.0 billion in 2022; at a CAGR of 3%.

In 2010, the medical device market in Switzerland was worth $2.4 billion, which increased to $3.1 billion in 2017. The main segments were in vitro diagnostics, cardiovascular devices, nephrology and urology devices, orthopedic devices and healthcare IT. The increasing elderly population and high investment in R&D expenditure are expected to drive the growth of pharmaceutical market.

More than a third of Swiss exports come from the pharmaceutical industry, making it a major contributor to the Swiss economy.In 2017, pharmaceutical exports amounted to $70.3 billion. In order to further support the growth and secure the country’s role as a leader in innovation, the Swiss government introduced the Innovation Park in 2016, with two hubs associated with the Federal Institutes of Technology.

The latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Switzerland", is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Switzerland. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Switzerland. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Switzerland, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Octapharma, Basilea, Actelion, Novartis and Roche) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Roche Diagnostics, DePuy Synthes, Agfa and Coloplast)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Switzerland
  • Porter’s five forces analysis for pharmaceutical and medical devices market of Switzerland
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Swiss healthcare market.
Reasons to buy

This report will enhance your decision-making capability by allowing you to:
  • Develop business strategies by understanding the trends shaping and driving the Swiss healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the Swiss healthcare market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter’s Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges
  • Appendix
List of Tables
Table 1: Pharmaceutical Market, Distribution Channels, Switzerland, 2016
Table 2: Pharmaceutical Market, Switzerland, Self Medication Product Category Sales ($m), 2016
Table 3: Pharmaceutical Market, Switzerland, Major therapeutic groups based on drug sales ($m), 2015
Table 4: Medical Device Market, Switzerland, Revenue by Segment ($m) and share (%), 2017
Table 5: IVD Devices Market, Switzerland, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 6: Cardiovascular Devices Market, Switzerland, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 7: Nephrology and Urology Devices Market, Switzerland, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 8: Orthopedic Devices Market, Switzerland, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 9: Healthcare IT Market, Switzerland, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 10: Fees for Market Authorization Procedure, Switzerland, 2018
Table 11: Patent Fees, Switzerland, 2018
Table 12: Trademark Fees, Switzerland, 2018
Table 13: Clinical Trial Process Fees, Switzerland, 2018
Table 14: Trade Fairs, Switzerland

List of Figures
Figure 1: Pharmaceutical Market, Switzerland, Revenue ($bn), 2010-2017
Figure 2: Medical Device Market, Switzerland, Revenue ($bn), 2010-2017
Figure 3: Country Profile, Switzerland, 2018
Figure 4: Pharmaceutical Market, Switzerland, Revenue ($bn), 2010-2017
Figure 5: Pharmaceutical Market, Switzerland, Revenue Forecast ($bn), 2018-2022
Figure 6: Pharmaceutical Exports ($bn), Switzerland, 2010-2017
Figure 7: Top Export Partners, Switzerland, 2017
Figure 8: Pharmaceutical Imports ($bn), Switzerland, 2010-2017
Figure 9: Top Import Partners, Switzerland, 2017
Figure 10: Distribution Channels, Switzerland
Figure 11: Pharmaceutical Market, Switzerland, Major therapeutic groups based on drug sales ($m), 2015
Figure 12: Pharmaceutical Market, Switzerland, Major Players
Figure 13: Medical Device Market, Switzerland, Revenue ($bn), 2010-2017
Figure 14: Medical Device Market, Switzerland, Revenue Forecast ($bn), 2018-2022
Figure 15: Medical Device Market, Switzerland, Revenue by Segment ($m), 2017
Figure 16: IVD Devices Market, Switzerland, Revenue ($m), 2010-2017
Figure 17: IVD Devices Market, Switzerland, Market Share of Major Players (%), 2017
Figure 18: Cardiovascular Devices Market, Switzerland, Revenue ($m), 2010-2017
Figure 19: Cardiovascular Devices Market, Switzerland, Market Share of Major Players (%), 2017
Figure 20: Nephrology and Urology Devices Market, Switzerland, Revenue ($m), 2010-2017
Figure 21: Nephrology and Urology Devices Market, Switzerland, Market Share of Major Players (%), 2016
Figure 22: Orthopedic Devices Market, Switzerland, Revenue ($m), 2010-2017
Figure 23: Orthopedic Devices Market, Switzerland, Market Share of Major Players (%), 2016
Figure 24: Healthcare IT Market, Switzerland, Revenue ($m), 2010-2017
Figure 25: Healthcare IT Market, Switzerland, Market Share of Major Companies (%), 2015
Figure 26: Diagnostic Market, Switzerland, Revenue ($bn), 2010-2017
Figure 27: Diagnostic Market, Switzerland, Revenue ($bn), 2018-2022
Figure 28: Medical Device Market, Switzerland, Revenue ($bn) of Major Companies, 2016
Figure 29: Deal Value and Deal Count, Pharmaceutical Market, Switzerland, 2017-2018
Figure 30: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Switzerland, 2017-2018
Figure 31: Deal Value and Deal Count Sub-types, Pharmaceutical Market, Switzerland, 2017-2018
Figure 32: Top 5 therapy area by deal value, Pharmaceutical Market, Switzerland, 2017-2018
Figure 33: Top 5 therapy area by deal number, Pharmaceutical Market, Switzerland, 2017-2018
Figure 34: M&A deals by therapy area, Pharmaceutical Market, Switzerland, 2017-2018 (By value and by number)
Figure 35: Venture Financing deals by therapy area, Pharmaceutical Market, Switzerland, 2017-2018 (By value and by number)
Figure 36: Private Equity deals by therapy area, Pharmaceutical Market Switzerland, 2017-2018 (By value and by number)
Figure 37: Medical Device Market Deals (by deal value, $m), Switzerland, 2017-2018
Figure 38: Medical Device Market Deals (by deal count), Switzerland, 2017-2018
Figure 39: Medical Device Market Deals Share (by deal count), Switzerland, 2017-2018
Figure 40: Medical Device Market Deals Share (by deal value), Switzerland, 2017-2018
Figure 41: Medical Device, Switzerland, Top Therapy Area by Deal Value, 2017-2018
Figure 42: Medical Devices, Switzerland, Top Therapy Area by Deal Number, 2017-2018
Figure 43: Medical Devices, Switzerland, M&A Deals by Therapy Area, 2017-2018
Figure 44: Medical Devices, Switzerland, VF Deals by Therapy Area, 2017-2018
Figure 45: Medical Devices, Switzerland, Private Equity Deals by Therapy Area, 2017-2018
Figure 46: Overview of Healthcare System, Switzerland, 2015
Figure 47: Drug Reimbursement Process, Switzerland, 2017
Figure 48: Out-of-Pocket Expenditure (% of total expenditure on health), Switzerland, 2010-2017
Figure 49: Change in Price Trend in Drug Sector (%), Switzerland, 2010-2017
Figure 50: Swissmedic, Organizational structure, Switzerland, 2018
Figure 51: Market Authorization Procedure, Switzerland, 2018
Figure 52: Conformity Assessment of Class I Medical Devices, EU, 2018
Figure 53: Conformity Assessment of Class IIa Medical Devices, EU, 2018
Figure 54: Conformity Assessment of Class IIb Medical Devices, EU, 2018
Figure 55: Conformity Assessment of Class III Medical Devices, EU, 2018
Figure 56: National Patent Approval Process, Switzerland, 2018
Figure 57: European Patent Approval Process, EU, 2018
Figure 58: National Trademark Approval Process, Switzerland, 2018
Figure 59: Clinical Trial Regulation Process, Switzerland, 2018
Figure 60: Labelling and Packaging Regulations, Switzerland, 2018
Figure 61: Hospitals (Number), Switzerland, 2010-2017
Figure 62: Hospital Bed by Type of Care (Number), Switzerland, 2010-2017
Figure 63: Diagnostic Equipment (Number), Switzerland, 2010-2017
Figure 64: Hospital Beds (per 1,000 population), Switzerland, 2010 - 2017
Figure 65: Life Expectancy (years), Switzerland, 2010-2017
Figure 66: Immunization Rate (%), Switzerland, 2010-2017
Figure 67: Major Causes of Mortality, No. of deaths (‘000), Switzerland, 2012
Figure 68: Major Causes of Male Mortality, No. of deaths (‘000), Switzerland, 2015
Figure 69: Major Causes of Female Mortality, No. of deaths (‘000), Switzerland, 2015
Figure 70: Disability-Adjusted Life Years by Major Disease (‘000), Switzerland, 2015
Figure 71: Physicians (per 1,000 population), Switzerland, 2010-2017
Figure 72: Nurses (per 1,000 population), Switzerland, 2010-2017
Figure 73: Dentists, (per 1,000 population), Switzerland, 2010-2017
Figure 74: Pharmacists, (per 1,000 population), Switzerland, 2010-2017
Figure 75: PM2.5 (µg per m3), Switzerland, 2010-2017
Figure 76: CO2 Emissions (k tons), Switzerland, 2010-2017
Figure 77: Healthcare Expenditure (% of GDP), Switzerland, 2010-2017
Figure 78: Public-Private Share (%), Switzerland, 2010-2017
Figure 79: Major Components of Healthcare Spending (%), Switzerland, 2011
Figure 80: Spending in R&D by sector (share %), Switzerland, 2015
Figure 81: Trade Associations, Switzerland
Figure 82: Opportunities & Challenges, Switzerland
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll